Available in Puerto Rico, Brazil
Treatment-naïve elderly and/or frail patients with DLBCL will be treated with
acalabrutinib in combination with rituximab in a single arm.
Study details include the following:
- The study duration will be up to 108 weeks for each patient, including up to 28 days
for screening and 104 weeks of treatment and follow-up.
- The treatment duration will be up to 8 cycles for rituximab and 28 cycles for
acalabrutinib both beginning at cycle 1.
80Patients around the world
